FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:802-803 September 14, 2000 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Childs, R. PubMed Citation

In this issue of the Journal, Childs and colleagues present preliminary evidence that in patients with metastatic renal-cell cancer, infusions of allogeneic hematopoietic stem cells after a preparative regimen that does not ablate the bone marrow (nonmyeloablative stem-cell transplantation) may be an effective treatment.¹ This report opens new therapeutic possibilities not only for metastatic renal-cell cancer but also for other solid tumors that are resistant to conventional chemotherapy and radiotherapy.

The basis of this treatment rests in part on observations that were made in patients who were treated with the classic approach to certain types of leukemia: very high doses . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., Slavin, S. (2006). Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Blood 107: 1564-1569 [Abstract] [Full Text]  
• Andersson, G., Illigens, B. M. W., Johnson, K. W., Calderhead, D., LeGuern, C., Benichou, G., White-Scharf, M. E., Down, J. D. (2003). Nonmyeloablative conditioning is sufficient to allow engraftment of EGFP-expressing bone marrow and subsequent acceptance of EGFP-transgenic skin grafts in mice. Blood 101: 4305-4312 [Abstract] [Full Text]  
• Or, R., Shapira, M. Y., Resnick, I., Amar, A., Ackerstein, A., Samuel, S., Aker, M., Naparstek, E., Nagler, A., Slavin, S. (2003). Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101: 441-445 [Abstract] [Full Text]  
• Kim, S.-H. M., Azam, T., Yoon, D.-Y., Reznikov, L. L., Novick, D., Rubinstein, M., Dinarello, C. A. (2001). Site-specific mutations in the mature form of human IL-18 with enhanced biological activity and decreased neutralization by IL-18 binding protein. Proc. Natl. Acad. Sci. USA 98: 3304-3309 [Abstract] [Full Text]